CONTINGENT CONSIDERATION LIABILITY (Details Narrative) - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2017 |
Sep. 30, 2017 |
Jun. 30, 2017 |
Mar. 31, 2017 |
Dec. 31, 2016 |
Sep. 30, 2016 |
Jun. 30, 2016 |
Dec. 31, 2017 |
Dec. 31, 2017 |
Dec. 31, 2016 |
Dec. 31, 2015 |
Mar. 31, 2016 |
|||||||||||||||||||||||||
Contingent Consideration liability | $ 12,085,859 | $ 12,085,859 | ||||||||||||||||||||||||||||||||||
Gain on Settlement of Contingent Consideration Liability | $ 4,991,571 | $ (4,991,571) | (4,991,571) | |||||||||||||||||||||||||||||||||
Loss on Fair Market Valuation of Contingent Consideration | 4,426,047 | (668,694) | ||||||||||||||||||||||||||||||||||
Contingent consideration, shares issued value | $ 4,789,638 | |||||||||||||||||||||||||||||||||||
Additional shares clawed-back, shares | 2,280,000 | 2,280,000 | 2,280,000 | |||||||||||||||||||||||||||||||||
Additional shares clawed-back, value | $ 9,684,268 | $ 9,684,268 | $ 9,684,268 | |||||||||||||||||||||||||||||||||
Market-Based Claw back associated with common stock | 2,340,000 | 2,340,000 | 2,340,000 | |||||||||||||||||||||||||||||||||
Additional shares clawed-back pursuant to disputes between the sellers | 34,200,000 | 34,200,000 | 34,200,000 | |||||||||||||||||||||||||||||||||
Black Oak [Member] | ||||||||||||||||||||||||||||||||||||
Contingent Consideration liability | 12,085,858 | $ 12,655,740 | $ 12,306,882 | $ 12,085,858 | $ 12,754,553 | |||||||||||||||||||||||||||||||
Adjustment to Goodwill | (98,812) | [1] | (348,858) | [2] | 447,670 | [2] | ||||||||||||||||||||||||||||||
Gain on Settlement of Contingent Consideration Liability | $ 98,812 | |||||||||||||||||||||||||||||||||||
April 1, 2016 (Acquisition Date) [Member] | ||||||||||||||||||||||||||||||||||||
Contingent Consideration liability | $ 12,754,553 | $ 12,754,553 | $ 12,754,553 | |||||||||||||||||||||||||||||||||
April 1, 2017 (Acquisition Date) [Member] | ||||||||||||||||||||||||||||||||||||
Final contingent consideration | $ 16,500,000 | |||||||||||||||||||||||||||||||||||
Contingent consideration, shares issued | 1,210,000 | |||||||||||||||||||||||||||||||||||
Contingent consideration, shares issued value | $ 4,700,000 | |||||||||||||||||||||||||||||||||||
Contingent consideration, cash payment | 2,100,000 | |||||||||||||||||||||||||||||||||||
Shares released from escrow, value | $ 14,400,000 | |||||||||||||||||||||||||||||||||||
Therapeutics Medical Acquisition[Member] | ||||||||||||||||||||||||||||||||||||
Description of contingent consideration arrangements |
In the acquisition of assets from Therapeutics Medical, the Company may be required to issue an additional Convertible Promissory Note to the seller based on the following calculation (the Therapeutics Contingent Consideration):
|
|||||||||||||||||||||||||||||||||||
Contingent Consideration liability | 4,000 | 4,000 | $ 4,000 | |||||||||||||||||||||||||||||||||
Present value of contingent consideration liability | 3,200 | 3,200 | $ 3,200 | |||||||||||||||||||||||||||||||||
Description for likelihood of payouts related to contingent consideration |
In determining the likelihood of payouts related to the Therapeutics Contingent Consideration, the probabilities for various scenarios (e.g., a greater than 98% probability that the minimum amount of Therapeutics Contingent Consideration will not be payable), as well as the discount rate used in the Companys calculations, were based on internal projections, all of which were vetted by the Companys senior management |
|||||||||||||||||||||||||||||||||||
Black Oak acquisition [Member] | ||||||||||||||||||||||||||||||||||||
Contingent Consideration liability | 12,754,553 | 12,754,553 | $ 12,754,553 | |||||||||||||||||||||||||||||||||
Description for likelihood of payouts related to contingent consideration |
In determining the likelihood of payouts related to the Black Oak Contingent Consideration, the probabilities for various scenarios (e.g., a 75% probability that the maximum amount of Black Oak Contingent Consideration will be payable), as well as the discount rate used in the Companys calculations were based on internal projections, all of which were vetted by the Companys senior management |
|||||||||||||||||||||||||||||||||||
Expected contingent consideration liability | 15,305,463 | 15,305,463 | $ 15,305,463 | |||||||||||||||||||||||||||||||||
Black Oak acquisition [Member] | Holdback Consideration [Member] | ||||||||||||||||||||||||||||||||||||
Description for determination of market-based claw back amount |
The Market-Based Clawback Amount is determined as follows:
In no event will the Market-Based Clawback Amount exceed 50% of the Holdback Consideration. |
|||||||||||||||||||||||||||||||||||
Description for determination of performance-based claw back amount |
The Performance-Based Clawback Amount is determined as follows:
|
|||||||||||||||||||||||||||||||||||
Black Oak acquisition [Member] | Performance-Based Cash Consideration [Member] | ||||||||||||||||||||||||||||||||||||
Due date description |
To be paid on approximately the one-year anniversary date of the closing of the Black Oak merger |
|||||||||||||||||||||||||||||||||||
Description for determination of performance-based cash consideration |
Pursuant to the Merger Agreement, the Group B Shareholders may receive cash consideration of up to approximately $2,088,000 to be paid on approximately the one-year anniversary date of the closing of the Black Oak merger, to be determined as follows:
For example, pursuant to the above formula, if the revenue in Year 1 equals $16,666,666, then the Performance-Based Cash Consideration would be $2,088,000. |
|||||||||||||||||||||||||||||||||||
Black Oak acquisition [Member] | Performance-Based Cash Consideration [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||
Cash consideration payable | $ 2,088,000 | $ 2,088,000 | $ 2,088,000 | |||||||||||||||||||||||||||||||||
|